It is noteworthy that, even though the ability of C3 and C7 to affect the RAD54-BLM interaction was lower than that of C17, all the 3 compounds were capable of overcoming drug resistance in preclinical models and thus potentially act as chemosensitizers during camptothecin-, oxaliplatin-, and cisplatin-based colon cancer treatment. This evidence concerns the gene ATRX and colonic neoplasm.